Hypertriglyceridemia and Cardiovascular Risk: Mechanisms, Associated Conditions, and Management

Elevated triglycerides (TG) are an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and, at very high levels, for acute pancreatitis. They reflect remnant lipoprotein accumulation and insulin resistance.

Classification (Fasting)

  • Normal: <150 mg/dL (<1.7 mmol/L)
  • Borderline high: 150–199 mg/dL
  • High: 200–499 mg/dL
  • Very high: ≥500 mg/dL (pancreatitis risk ↑↑)

Cardiovascular Diseases Linked

  • Coronary heart disease (CHD): Remnant cholesterol (VLDL, IDL) infiltrates intima; pro-inflammatory, pro-thrombotic
  • Peripheral artery disease (PAD): Similar atherogenic process in lower extremities
  • Cerebrovascular disease: Ischemic stroke, TIA; carotid plaque progression
  • Acute pancreatitis: TG >1000 mg/dL (5–10% risk); >2000 mg/dL (10–20% risk); chylomicronemia syndrome

Pathophysiology

  • TG-rich lipoproteins (chylomicrons, VLDL) → lipolysis → remnant particles (cholesterol-enriched) → arterial retention
  • Remnants: Pro-inflammatory (↑ cytokines, adhesion molecules), pro-coagulant (↑ PAI-1, fibrinogen)
  • Associated with: Small dense LDL, low HDL, hyperglycemia, hypercoagulability → atherogenic dyslipidemia

Common Secondary Causes

  • Uncontrolled diabetes (↑ VLDL synthesis, ↓ LPL activity)
  • Obesity, insulin resistance, metabolic syndrome
  • Alcohol (even moderate)
  • Medications: Estrogen, corticosteroids, retinoids, protease inhibitors, β-blockers (non-vasodilating), thiazides, sirolimus
  • Hypothyroidism, nephrotic syndrome, CKD, liver disease
  • Genetic: Familial combined hyperlipidemia, familial hypertriglyceridemia, FCS (LPL, APOC2, APOA5, GPIHBP1 mutations)

Management

  • Lifestyle (first-line): Weight loss, carbohydrate restriction (esp. refined/sugars), alcohol avoidance, exercise, ω-3 fatty acids (2–4 g EPA/DHA)
  • Treat secondary causes (glycemic control, thyroid, medication review)
  • Pharmacotherapy (TG ≥500 or ASCVD risk + TG 200–499):
    • Fibrates (fenofibrate): ↓ TG 30–50%, ↑ HDL
    • Prescription ω-3 (icosapent ethyl 4 g/day): ↓ TG, ↓ CV events (REDUCE-IT)
    • Statins: Modest TG ↓ (10–30%); primary for LDL/ASCVD
    • Niacin: Less used (side effects, no added benefit on statins)
  • Pancreatitis prevention: TG <500 mg/dL target; very high TG → fibrate + ω-3 + strict diet ± insulin drip if acute

Hypertriglyceridemia is both a marker and mediator of metabolic-vascular risk. Comprehensive management addresses lifestyle, secondary causes, and targeted pharmacotherapy.

Cardiovascular Disease - Related Articles